

1 **Methods**

---

2 **Mice.** Female and male C57BL/6 (~20 g) mice were purchased at 7 weeks old from Charles River  
3 Laboratories (Montréal, Canada) and allowed 7 days of acclimation at the housing facility of  
4 CERVO Brain Research Center. Sexually experienced retired male CD-1 breeders (~40 g) of at  
5 least 4 months of age (Charles River Laboratories) were used as aggressors (AGG). *ROSA26iDTR*  
6 male mice and *PDGFR $\beta$ -P2A-CreERT2* female mice were purchased from Jackson Laboratory  
7 (Strain #007900 and #030201, respectively) and bred at the CERVO Brain Research Center.  
8 Offspring *PDGFR $\beta$ -CreERT2-iDTR* were used between 6-9 weeks of age. All mice were singly  
9 housed following CSDS and maintained on a 12h/12h light/dark cycle throughout. Room  
10 temperature was maintained between 19 and 23 °C and humidity was kept around 40–45%. Mice  
11 were provided with *ad libitum* access to water and food. All mouse procedures were performed in  
12 accordance with the Canadian Council on Animal Care (1993) as well as Université Laval animal  
13 care committee (Certificate #2022-1061, VRR-22-1061).

14 **Chronic social defeat stress (CSDS).** The male 10-day CSDS paradigm was performed as  
15 detailed in Golden et al.<sup>1</sup> and our recent studies<sup>2-4</sup>, and female 10-day CSDS was performed as  
16 previously described<sup>4,5</sup>. Briefly for females, urine of a particular male CD-1 was applied to the  
17 base of the tail (20  $\mu$ L), vaginal orifice (20  $\mu$ L) and upper back (20  $\mu$ L) of the female mouse then  
18 it was immediately subjected to physical interactions with an unfamiliar CD-1 previously screened  
19 for aggressive behavior (AGG) for 10 mins. After antagonistic interactions, experimental mice  
20 were removed and housed on the opposite side of the social defeat cage divider, allowing sensory  
21 contact, for the subsequent 24h period. Throughout the sessions, mice were monitored for  
22 aggressive interactions and mounting behaviours. A session was immediately stopped if persistent  
23 mounting or fighting causing physical wounding occurred. Unstressed control mice were housed  
24 two per cage on either side of a perforated divider and rotated daily in a similar manner without  
25 being exposed to the CD-1 AGG mice. Experimental and control mice were singly housed after  
26 the last bout of physical interaction and the social interaction (SI) test was conducted 24h later.  
27 Physical wounding was scored at the time of tissue collection, 24h after the SI test, and consisted  
28 of counting the number of tail bites on the experimental animals as well as the surface area ( $\text{cm}^2$ )  
29 of lower back lacerations, if applicable.

30 **Social interaction test (SI).** SI test was performed as previously described<sup>1-4</sup>, under red light  
31 conditions. Briefly, experimental, or unstressed mice were placed in a Plexiglass open field arena  
32 (50  $\text{cm}^2$ , Nationwide Plastics) containing a small wire cage placed at one end. Movements were  
33 monitored and recorded automatically for 2.5 min with a tracking system (AnyMaze™ 6.1,  
34 Stoelting Co) to determine baseline exploratory behaviour and locomotion in the absence of a  
35 social target (AGG). After this first trial, the animal was removed, and the arena cleaned. Next,  
36 exploratory behaviour in the presence of a novel male CD-1 AGG target inside the small wire  
37 animal cage was measured for 2.5 min and time spent in the interaction and corner zones and  
38 overall locomotion were compared. SI ratio was calculated by dividing the time spent in the  
39 interaction zone when the AGG was present vs absent. All mice with a SI ratio below 1.0 were  
40 classified as stress-susceptible (SS) and all mice with a SI ratio above 1.0 were classified as  
41 resilient (RES).

42 **Elevated plus maze (EPM).** EPM was performed as previously described<sup>2,4</sup>, under white light  
43 conditions. Mice were placed in the center of a black Plexiglas cross-shaped elevated plus maze  
44 (arms of 12 cm width  $\times$  50 cm length) for 5 min. The maze consists of a center area, two open

45 arms without walls and two closed arms with 40 cm high walls set on a pedestal 1 m above floor  
46 level. Locomotion was monitored and tracked using an automated system (AnyMaze™ 6.1  
47 Stoelting Co). Cumulative time spent in open arms or open arm extremities (furthest half), center,  
48 and closed arms as well as total locomotion was compared between groups.

49 **Splash test (ST).** The splash test was used to compare motivated grooming behaviour and  
50 performed under red-light conditions as previously described<sup>2,4</sup>. A 10% sucrose solution was  
51 sprayed 3-times on the lower back of the mice and time spent grooming over 5 min was videotaped  
52 and then recorded with a stopwatch by a blinded observer.

53 **Sucrose preference (SP) test.** Anhedonic responses were evaluated with the SP test, as previously  
54 described<sup>2,4</sup>. Mice were habituated for 2-days prior to SP by replacing water bottles with two 50  
55 mL conical tubes with sipper tops filled with water. Next, water from one of the tubes was replaced  
56 with a 1% sucrose solution and mice were allowed to drink *ad libitum* for a 48h period. Tubes  
57 were switched after 24h to prevent placement preference. Both water and sucrose tubes were  
58 weighed before, after 24h and at the end (48h) of the SP test. Sucrose preference was calculated  
59 by dividing the total amount of sucrose consumed by the total amount of fluid consumed over the  
60 2-d of sucrose availability.

61 **Forced swim test (FST).** FST was used to evaluate helplessness, as previously described<sup>2,4</sup>. Mice  
62 were placed into a 4L glass beaker filled with 3L of room temperature water (25°C), under bright  
63 light conditions and videotaped for 6 mins. Immobility, defined as no or minor movement  
64 necessary to keep the nose above water, was measured by a blinded observer.

65 **Transcriptional profiling of mouse tissue.** Prefrontal cortex (PFC) or nucleus accumbens (NAc)  
66 samples were collected and processed as described previously<sup>2,4</sup>. Briefly, bilateral 2.0 mm brain  
67 punches were collected from 1.0 mm coronal slices after rapid decapitation and flash frozen at -  
68 80°C until use. RNA was isolated with TRIzol (Invitrogen) homogenization and chloroform layer  
69 separation using the Pure Link RNA mini kit (Life Technologies). RNA concentration was  
70 determined with NanoDrop (ThermoFisher) and reversed transcribed to cDNA using the Maxima-  
71 H-minus cDNA synthesis kit (Fisher Scientific). Each qPCR reaction (well) contained 3ng of  
72 sample cDNA, 5µL of Power up SYBR green (Fisher Scientific), 1µL of PrimeTime qPCR primer  
73 (Integrated DNA Technologies) and 1µL ddH2O. Plates were heated at 95°C for 2mins, followed  
74 by 40 cycles of 95°C for 15s, 60°C for 33s and 72°C for 33s. The  $\Delta\Delta Ct$  method was used for  
75 analysis, using mouse *Gapdh* as a housekeeping gene. Primer pairs (Integrated DNA  
76 Technologies) are listed in the **Suppl.Table 12**.

77 **Microvessel isolation for RNA-sequencing.** Microvessel isolation was performed as previously  
78 described<sup>6</sup>, with minor modifications. Briefly, 4 bilateral 2-mm punches (30-50 mg tissue) from  
79 1.0 mm coronal brain slices of PFC or NAc were collected after rapid decapitation in MCDB 131  
80 media (Gibco, 10372-019). Samples were homogenized with a 7mL Dounce homogenizer in  
81 MCDB 131 containing 0.5% bovine serum albumin (BSA) and centrifuged at 2000g for 10 minutes  
82 at 4°C. Pellets were then resuspended in a 18.75% (wt/vol) 70-kDa Dextran solution (Sigma,  
83 31390-25G) and ultracentrifuged at 12000 rpm for 21 mins at 4°C (SW60 rotor, Beckman Coulter).  
84 Myelin layer and debris were removed by aspiration, before transferring pellets containing  
85 microvessel fragments to a 20-µm cell strainer and washing with hypotonic solution (20 mM Tris-  
86 HCl, 10 mM NaCl, 3 mM MgCl<sub>2</sub> in nuclease-free water). Finally, microvessels were collected by  
87 inverting filter onto a new tube and eluting with 1.4 mL hypotonic solution. Suspension was

88 centrifuged at 2000g for 10 minutes at 4°C, and pelleted cells resuspended in 200 µL of Trizol for  
89 downstream applications.

90 **Immunohistochemistry and quantification of mouse pericyte morphology.** 24h after the SI  
91 test, mice were anesthetized with a mixture of ketamine (100mg/kg of body weight) and xylazine  
92 (10mg/kg of body weight). Animals were perfused with ice-cold 0.1M phosphate-buffered saline  
93 (PBS), brain were extracted and post-fixed overnight in 2% PFA at 4°C, then sliced on a vibratome  
94 (Leica) at 40µm thickness. Free-floating sections were washed in 0.1M PBS and incubated for 2h  
95 at room temperature (RT) in blocking solution containing 4% normal donkey serum (NDS) and  
96 0.4% Triton X-100 in 0.1M PBS, before overnight incubation at 4°C with primary antibodies  
97 diluted in blocking solution. The next day, after three washes in 0.1M PBS, sections were  
98 incubated with secondary antibodies and/or Lycopersicon Esculentum (Tomato) Lectin DyLight®  
99 for 2h. Sections were again washed, counterstained with DAPI, then mounted and coverslipped  
100 with ProLong Diamond Antifade Mountant (Invitrogen). Antibodies and concentration used are  
101 listed in **Suppl.Table 13**.

102 Twenty-micrometer-thick z-stack images of the region of interest were acquired on an LSM-700  
103 microscope with Apotome (Carl Zeiss). Images were taken using a 40x lens. For pericyte coverage  
104 analyses, 12 planes from 3 non-consecutive sections were acquired from each animal and analysed  
105 in Imaris 9.6.1 software (Oxford Instruments, UK).

106 **Immunohistochemistry and quantification of human pericyte morphology.** 20-µm human  
107 PFC sections on slides were post-fixed for 10 min in ice-cold methanol before a quick wash in  
108 0.1M PBS. Sections were incubated for 2h in blocking solution containing 4% NDS, 0.4% Triton  
109 X-100 in 0.1M PBS before being incubated overnight at 4°C in rabbit anti-PDGFRB (1:250,  
110 Abcam, ab32570) and sheep anti-CD31 (1:50, R&D, AF806). The next day, slides were washed  
111 three times in 0.1M PBS before incubation in anti-rabbit Alexa-Fluor 647 and anti-sheep Alexa-  
112 Fluor 594 for 2h at RT. Slides were washed, counterstained with DAPI, mounted and coverslipped  
113 with with ProLong Diamond Antifade Mountant (Invitrogen).

114 Five-micrometer-thick z-stack images of the region of PFC were acquired on an LSM-700  
115 microscope with Apotome (Carl Zeiss). Images were taken using a 20× lens with a resolution of  
116 2464x2056. Scaling was 0.173 µm x 0.173 µm x 1 µm in the x-y-z planes. Six planes from 2  
117 sections were acquired from each individual and analysed with the Imaris 9.6.1 software (Oxford  
118 Instruments, UK).

119 **Transmission electron microscopy (TEM).** 24h after the SI test, mice were anesthetized with a  
120 mixture ketamine (100mg/kg of body weight) and xylazine (10mg/kg of body weight). Animals  
121 were perfused with ice-cold 0.1M PBS followed with a mixture of 4% PFA and 2% glutaraldehyde  
122 in 0.1M PB. Brains were isolated and sectioned at 50mm using a Leica VT1000S vibratome (Leica  
123 Biosystems). Post-fixation and resin embedding were performed as previously described by  
124 Deerinck et al. (2022). Briefly, 50mm-brain sections were washed in PBS and incubated in 3%  
125 potassium ferrocyanide and 4% aqueous osmium tetroxide in 0.1M PB (pH 7.4) for 1h at room  
126 temperature, followed by incubation in a thiocarbohydrazide (1% w/v) solution at room  
127 temperature for 20 mins. Sections were subsequently incubated for 30 mins in a 2% aqueous  
128 osmium tetroxide solutionand dehydrated by increasing ethanol concentrations followed by  
129 propylene oxide. Afterward, post-fixed sections were embedded in Durcupan ACM Epoxy resin  
130 (Sigma-Aldrich) between Aclar sheets at 55°C for 72h. Ultrathin sections were generated at

131 80nm using a Leica EM UC6 ultramicrotome. Ten capillaries per animal were randomly  
132 photographed using a JEM-1400Flashtransmission electron microscope operating at 80kV and  
133 equipped with a 16MP digital camera (GATAN One View). For each capillary, a whole vascular  
134 profile (6000x) and a high-magnification mosaic (20,000x) were acquired for further analysis.  
135 Quantification of images was performed blindly in ImageJ.

136 **Focused Ion Beam-Scanning Electron Microscopy (FIB-SEM).** Sections containing region of  
137 interest were excised from ACLAR sheets and glued to Durcupan ACM Epoxy resin (Sigma-  
138 Aldrich) blocks. Tissue face was polished using a Leica Artos 3D ultramicrotome. Tissue  
139 containing resin block was cut, glued onto aluminum stub (Ted Pella) using CCC carbon adhesive  
140 paint (EMS), and coated with 30 nm of platinum using a Leica EM ACE600 sputter coater. The  
141 stub was loaded into a Zeiss Crossbeam 350 FIB-SEM. Region of interest containing blood  
142 vessel(s) was identified and ATLAS Engine 5 software (Fibics) was used to complete volume  
143 image acquisition. Briefly, exact region of interest was protected with platinum deposition and FIB  
144 trenching was performed to expose tissue face. Next, images were acquired at 5 nm resolution in  
145 x-and-y using the SE2 detector and SEM voltage at 1.4kV. Milling was performed at 20nm steps  
146 in z-direction using the FIB with the voltage at 30kV and current at 700pA. Image stacks were  
147 aligned, exported as TIFs, and uploaded into webKnossos software<sup>7</sup>. After unsupervised  
148 segmentation was performed and appropriate post-hoc corrections were completed, pericyte and  
149 endothelial morphologies and contacts were visualized.

150 **Region-specific ablation of pericytes.** This experiment was adapted from previously published  
151 work<sup>8,9</sup>. At 7 weeks of age, female and male *PDGFRβ-CreERT2-iDTR* mice were injected  
152 intraperitoneally with tamoxifen (40 mg/kg of body weight diluted in corn oil, Sigma Aldrich) for  
153 5 days and allowed to recover for 72h before stereotaxic injections. All surgeries were performed  
154 under aseptic conditions using anesthetic as previously described<sup>8</sup>. Mice were anesthetised with  
155 isoflurane (3-4% in O<sub>2</sub> for induction and 1-1.5% in O<sub>2</sub> for maintenance at 1L/min flow rate) and  
156 positioned in a small stereotaxic instrument (Harvard Apparatus). The skull surface was exposed,  
157 and 0.1 ng in 0.5 μL of diphtheria toxin (Sigma Aldrich) or vehicle (VEH, saline) was bilaterally  
158 infused in the PFC (bregma coordinates: anteroposterior +1.80mm; mediolateral +/- 0.35mm;  
159 dorsoventral -2.35mm), at a flow rate of 0.1μl/min. Mice were allowed to recover for 7 days before  
160 assessment of social, anxiety and depressive-like behaviors. After the last behavioral test, brains  
161 were collected to confirm pericyte depletion by immunohistochemistry.

162 **Bioluminescence for PHP.V1 serotype.** To confirm that systemic injection of the PHP.V1  
163 serotype could cross the BBB, 6-weeks old female CD1 mice were intravenously injected with an  
164 AAV2/PHP.V1-P2Pdgfb-Luc or an AAV2/PHP.V1-CAG-PDGFb-P2A-Luciferase (PHP.V1-  
165 Luc) AAV2/9-CAG-Luciferase (AAV2/9-Luc), a serotype with known limited penetration and  
166 CNS transduction<sup>10,11</sup>. CD1 mice were used for this experiment since black fur of C56BL/6J mice  
167 is not suitable for bioluminescence imaging<sup>12</sup>. At each timepoint, mice were intraperitoneally  
168 injected with D-Luciferine (Thermo Fisher, 150mg/kg of body weight) 25-30 minutes prior to  
169 imaging on the IVIS Spectrum 200 (Perkin Elmer, exposure time: 2 min). Mice were kept under  
170 isoflurane anesthesia during procedure (3-4% in O<sub>2</sub> for induction and 1-1.5% in O<sub>2</sub> for  
171 maintenance at 1L/min flow rate). Animals were imaged at the following time points: 1h prior to  
172 viral injection (baseline), D14, D21, D28, D35, D42.

173  
174 **Viral modulation of brain Pdgfb expression.** At 6 weeks of age, C57BL/6J female mice were  
175 intravenously injected with 2x10<sup>10</sup> VG of AAV2/PHP.V1- CAG-PDGFb-T2A-eGFP (PHP.V1-

176 *Pdgfb*) or AAV2/PHP.V1-CAG-eGFP (PHP.V1-GFP). A first cohort was subjected to a battery of  
177 depression- and anxiety-related behaviors in the absence of acute or chronic stressors. A second  
178 cohort was injected and exposed to 10-d CSDS before being subjected to the same battery of  
179 depression- and anxiety-related behaviors.

180

181 **Electrophysiological recordings.** Electrophysiological recordings were performed as previously  
182 described<sup>13</sup>. For the pericyte depletion cohort, female *PDGFRβ-CreERT2-iDTR* mice were  
183 injected intraperitoneally with tamoxifen for 5 days and allowed to recover for 72h before PFC  
184 stereotaxic injections of DTX or VEH. Mice were allowed to recover for 8 days before  
185 electrophysiological recordings of PFC pyramidal neurons (3 mice per group). For the PHP.V1  
186 virus cohort, C57BL/6J female mice were intravenously injected at 6 weeks of age with  $2 \times 10^{10}$   
187 VG of PHP.V1-*Pdgfb* or PHP.V1-GFP and allowed to recover for 21 days for virus expression (4  
188 mice per group). The day of recordings, mice were anesthetized with isoflurane and transcardially  
189 perfused with 10 mL of an ice-cold and freshly prepared NMDG-artificial cerebrospinal fluid  
190 (aCSF) solution containing: 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 2.5 mM KCl, 10 mM MgCl<sub>2</sub>, 20 mM HEPES, 0.5  
191 mM CaCl<sub>2</sub>, 24 mM NaHCO<sub>3</sub>, 8 mM D-glucose, 5 mM L-ascorbate, 3 mM Na-Pyruvate, 2 mM  
192 Thiourea 93 mM NMDG (osmolarity adjusted with sucrose to 300–310 mOsmol/l) and 2 mM  
193 kynurenic acid. Brains were then sliced at 250  $\mu$ m in ice-cold perfusion solution. Then, slices were  
194 immersed in a 32°C oxygenated perfusion solution for 10 minutes, before being incubated in  
195 HEPES-aCSF solution (1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 2.5 mM KCl, 10 mM MgCl<sub>2</sub>, 20 mM HEPES, 0.5  
196 mM CaCl<sub>2</sub>, 24 mM NaHCO<sub>3</sub>, 2.5 mM D-glucose, 5 mM L-ascorbate, 1 mM Na-Pyruvate, 2 mM  
197 Thiourea, 92 mM NaCl, 20 mM Sucrose for 1h at room temperature. Finally, slices were  
198 transferred to a recording chamber on the stage of an upright microscope (Zeiss) where it was  
199 perfused at a rate of 3–4 ml/min with artificial cerebrospinal solution (aCSF in mM: 120 NaCl, 5  
200 HEPES, 2.5 KCl, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, 2 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 2.5 glucose, 24 NaHCO<sub>3</sub>, 7.5 sucrose). The  
201 perfusion chamber and the aCSF were kept at 32°C and all solutions were oxygenated at 95% O<sub>2</sub>  
202 and 5% CO<sub>2</sub>. A water immersion x60 objective and a video camera (Zeiss, Germany) were used  
203 to visualize the glutamatergic pyramidal neurons in the mPFC. Whole-cell voltage-clamp  
204 recordings were performed with an Multiclamp 700B amplifier (Molecular Devices, San Jose, CA)  
205 using borosilicate patch electrodes (3–5 M $\Omega$  resistance). Pipettes were filled with an intracellular  
206 patch solution containing (in mmol/l): 115 Cesium methanesulfonate, 20 Cesium chloride, 10  
207 HEPES, 2.5 MgCl<sub>2</sub>, 4 Na<sub>2</sub>-ATP, 0.4 Na-GTP, 10 Na-phosphocreatine, 0.6 EGTA, 5 QX314 and  
208 0.2% Biocytin (pH 7.35). Signals were filtered at 5 kHz using a Digidata 1500B data acquisition  
209 interface (Molecular Devices, San Jose, CA) and acquired using pClamp 10.6 software (Molecular  
210 Devices, San Jose, CA). Pipette and cell capacitances were fully compensated. Passive membrane  
211 properties were measured. Spontaneous excitatory postsynaptic currents (sEPSCs) were recorded  
212 at -60 mV, and spontaneous inhibitory postsynaptic currents (sIPSCs) at 0 mV. A total of 63  
213 neurons (27 neurons in 6 mice for pericyte ablation experiments, and 36 neurons from 8 mice in  
214 PHP.V1 experiments) was recorded. For the neurons where both sEPSCs and sIPSCs were  
215 recorded, a frequency ratio of sEPSCs/sIPSCs was calculated.

216 **Human postmortem tissue collection.** As previously described<sup>4</sup>, human brains were collected and  
217 NAc or PFC tissue samples dissected by the Suicide section of the Douglas-Bell Canada Brain  
218 Bank (DBCBB; <https://douglasbrainbank.ca>) under the approval of the institution's Research  
219 Ethics Board. All brains are donated to the Suicide section of the DBCBB by familial consent  
220 through the Quebec Coroner's Office. In addition to consenting to tissue donation for research and  
221 access to relevant (including medical) files, families agree to participate in the psychological

222 autopsy that is conducted two months after the death of their next of kin. Blood toxicology was  
223 performed and individuals with evidence of drugs or psychotropic medications were excluded.  
224 Individuals with a known history of neurological disorders or head injury were also excluded.  
225 Demographic characteristics associated with each sample are listed in **Suppl. Table 3**. Clinical  
226 records and interviews were obtained for each case and reviewed by three or four mental health  
227 professionals to establish independent diagnoses followed by a consensus diagnosis in line with  
228 the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria. Groups were  
229 matched as closely as possible for gender, age, race, pH, postmortem interval. All experiments  
230 were performed with the approval of Université Laval and CERVO Brain Research Center Ethics  
231 Committee Neurosciences et santé mentale (Project #2019-1540).

232  
233 **Human blood collection and serum extraction.** All human blood serum samples were provided  
234 by Signature Bank from the Centre de recherche de *l'Institut universitaire en santé mentale de*  
235 *Montréal* (CR-IUSMM) under approval of the institution's Ethics Committee. Samples from  
236 volunteers with MDD or BPD were collected at the emergency room of the *Institut Universitaire*  
237 *en santé Mentale de Montréal* of CIUSSS de l'Est-de-Montreal and samples from healthy  
238 volunteers at the CRIUSMM. All donors provided informed consent and signed a 7-page document  
239 detailing the goals of the Signature Bank, participants' involvement (questionnaires and tissue  
240 sampling), advantages vs risks, compensation, confidentiality measures, rights as participant and  
241 contact information. Subjects with a known history of drug abuse were excluded. Demographic  
242 characteristics associated with each sample are listed in **Suppl. Table 11**. Depressive behaviours  
243 were assessed by the Patient Health Questionnaire (PHQ-9), which scores each of the nine  
244 Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria<sup>14</sup>. All experiments were  
245 performed under the approval of Université Laval and CERVO Brain Research Center Ethics  
246 Committee Neurosciences et santé mentale (Project #2019-1540).

247  
248 **Quantification of human and mouse serum analytes.** Human or mouse soluble PDGF-BB levels  
249 were assayed using the Bio-Plex Human Cytokine PDGF-BB Set (Bio-Rad #171B5024M) or the  
250 Bio-Plex Mouse Cytokine PDGF-BB Assay (#ZD0000003N), respectively and according to the  
251 manufacturer's protocol. Plates were read on a Bio-Plex 3D system (Bio-Rad) with 50 bead events  
252 per well, and data reduced against a four-parameter logistic curve using the Gen 5.0 software.  
253 Samples with a coefficient of variation above 20% between duplicates were removed from the  
254 analysis.

255  
256 **Cell culture experiments.**  
257 **Cell lines.** Mouse brain endothelial cells (bEnd.3i) were purchased from ATCC (# CRL-2299) and  
258 cultured according to manufacturer's instructions. Human brain endothelial cells (HBEC) and  
259 Human brain vascular pericytes (HBVP) were purchased from ScienCell (#1000 and #1200,  
260 respectively) and cultured according to manufacturer's instructions. bEND.3i and HBEC were  
261 cultured on 0.1% (w/v) gelatin-coated vessels in Dulbecco's Modified Eagle Medium F12  
262 (DMEM: F12, Gibco #11330033) supplemented with 10% Fetal Bovine Serum (FBS, Corning  
263 #35-077-CV), 1X Endothelial cell growth supplement (ECGS, ScienCell #1052) and Gentamicin  
264 (25 $\mu$ g/mL, ThermoFisher # 15750060). HBVP were cultured on poly-D-lysine-coated vessels  
265 (PDL, 5 $\mu$ g/cm<sup>2</sup>, Sigma-Aldrich #A-003-M) in Pericyte Medium (ScienCell #1201). For all  
266 experiments detailed below, cell seeding densities were determined according to manufacturer's

267 recommended densities, unless stated otherwise (bEND.3i/HBEC:  $5 \times 10^4$  cells/cm<sup>2</sup>, HBVP:  $6 \times$   
268  $10^4$  cells/cm<sup>2</sup>). Cells were used between passages (P)3 and P5, inclusively.

269  
270 **Transcriptional profiling of virus-infected cells.** bEND.3i were seeded on a 6-well plate. Once  
271 confluent, cells were infected with PHP.V1-GFP or PHP.V1-*Pdgfb* ( $1 \times 10^6$  VG per well) for 72h  
272 (n=6 per group). This timepoint was previously validated to efficiently transduce endothelial cells  
273 *in vitro*<sup>10</sup>. Then, cells were collected in 0.5 mL Trizol and processed as described above (see  
274 *Transcriptional profiling of mouse tissue*) for qPCR.

275  
276 **Transendothelial Electrical Resistance (TEER).** bEND.3i were seeded on 12-mm transwell  
277 polycarbonate culture inserts (Millicell, Millipore #PITP01250) with 3  $\mu$ m pore size (n=2 per  
278 group) Three days later, cells were infected with PHP.V1-GFP or PHP.V1-*Pdgfb* ( $1 \times 10^6$  VG per  
279 well) and TEER measurements were taken using the Millicell® ERS-2 Electrical Resistance  
280 System. Gelatin-coated insert with no cells was used as a blank. Electrodes were habituated in  
281 complete growth media at room temp for 10 mins before reading resistance across cell monolayers.  
282 TEER was calculated as resistance of sample minus resistance of blank, multiplied by membrane  
283 surface area (0.6 cm<sup>2</sup>) and normalized to PHP.V1-GFP.

284 **Scratch wound assay.** bEND.3i were seeded in a 24-well plate. Once confluent, cells were  
285 infected with PHP.V1-GFP or PHP.V1-*Pdgfb* ( $1 \times 10^6$  VG per well) for 72h (n=4 per group). Then,  
286 a vertical wound was introduced down the center of each well. Cells were washed with PBS and  
287 provided with fresh medium. Brightfield wound images were immediately acquired (baseline, T0)  
288 then 1, 6 and 24h later. Images were blindly processed using the Wound Healing plugin in ImageJ.  
289 Briefly, relative wound healing was determined as % image area devoid of cells using T0 value as  
290 0% (with 100% being a well where cell density inside the wound is the same as the cell density  
291 outside the initial wound).

292 **In vitro exposition to human serum.** This experiment was adapted from previous studies<sup>15,16</sup>. To  
293 minimize intra-individual variability of serum contents and maximise reproducibility across  
294 experiments, age-matched groups of pooled serum (n=15 individuals per group) were created  
295 based upon PHQ-9 scores (CTRL: PHQ-9 total score < 4 without anhedonia or depressed mood,  
296 MDD: PHQ-9 total score > 15 with anhedonia and depressed mood).

297 For direct serum exposition studies, HVBP were incubated with 10% CTRL or MDD pooled serum  
298 in fresh media for 24h. Then, serum was replaced with fresh media for an additional 24h to produce  
299 pericyte secretome. Both cells and secretome were then collected for downstream experiments.  
300 For indirect serum exposition studies, HBEC were first incubated with 10% CTRL or MDD pooled serum  
301 in fresh media for 24h. Then, serum was replaced with fresh media for an additional 24h to produce  
302 endothelial secretome. Subsequently, 100  $\mu$ L of endothelial secretome was collected for  
303 downstream experiments and the rest was transferred to naïve HBVP for 24h. At this point, HBEC  
304 were collected. Finally, HBVP were provided with fresh media for an additional 24h to produce  
305 pericyte secretome, after which HBVP and secretome were collected for downstream experiments.

306  
307 **Flow cytometry for PDGFR $\beta$  internalization.** This experiment was performed as previously  
308 described with minor modifications<sup>17</sup>. HBVP were grown in a 12-well plate and treated for 3h or  
309 24h, then dissociated using StemPro Accutase for 5 mins at 37°C (Gibco, A11105). Samples were  
310 passed through a 70  $\mu$ m cell strainer (Miltenyi #130-110-916) and centrifuged at 300g for 5 mins.  
311 Supernatant was removed and pellets were resuspended in cold buffer (1% FBS in PBS) as a wash.

312 For cell surface PDGFR $\beta$  labelling, samples were centrifuged at 300g for 5 mins and supernatant  
313 discarded before incubation with anti-human CD140b-PE (BD Biosciences, #558821) for 20 mins,  
314 on ice. Next, cells were washed in 1 mL cold buffer and centrifuged again at 300g for 5 mins.  
315 Supernatant was discarded and pellet was resuspended in 7-aminoactinomycin D (7-AAD, 5  $\mu$ L in  
316 100  $\mu$ L cold buffer, BD Biosciences #51-68981E) for 15 mins. Volume was adjusted to 300  $\mu$ L  
317 with cold buffer and fluorescence was measured on a BD LSR II. At least 10,000 events were  
318 gated based on forward and side scatter, excluding 7-AAD+ cells. Gating strategy is shown in  
319 **Suppl. Fig.8**. For total PDGFR $\beta$  labelling, cells in cold buffer were fixed by adding an equal  
320 volume of 8% PFA for 20 mins. Then, cells were washed and permeabilized with PBS+0.1%  
321 Triton X-100 and centrifuged at 300g for 5 mins. Supernatant was discarded and pellets were  
322 resuspended in anti-human CD140b-PE for 20 mins, at RT. Cells were washed once more in cold  
323 buffer, supernatant discarded and resuspended 7-AAD for 15 mins. Volume was adjusted to 300  
324  $\mu$ L with cold buffer and fluorescence was measured on a BD LSR II. At least 10,000 events were  
325 gated based on forward and side scatter, including 7-AAD+ cells. A small volume of fixed cell  
326 suspension was mounted on a slide and imaged. Data were analyzed with FACS Diva software  
327 (BD Biosciences, v.6.1.3).  
328

329 **Protein extraction, SDS-PAGE and Western blotting.** HBVP were treated with human serum  
330 as described above for 3h, before collection in Lysis buffer (Cell Signaling #9803S) supplemented  
331 with protease inhibitor cocktail (Cell Signaling #5871). Samples were incubated for 30 mins on  
332 ice before centrifugation at 13 000 rpm for 10 mins, at 4°C. Protein concentrations were  
333 determined using the Pierce BCA Protein Assay Kit (Thermo 23225). Equal amounts of protein  
334 samples were separated by SDS-PAGE (4–15% polyacrylamide gels, Bio-Rad #4568084) and  
335 transferred to PVDF membranes (0.45  $\mu$ m pore size, Milipore IPFL00005). Then, membranes were  
336 blocked with 5% BSA in Tris-Buffered saline supplemented with 0.1% Tween-20 (TBST) for 1h  
337 on agitation and incubated overnight with primary antibodies. The next day, membranes were  
338 washed 3x10-min with TBST and incubated for 2 h with secondary antibodies. Membranes were  
339 washed four more times with TBST and then antibody binding was detected using Clarity Max  
340 ECL Substrate-Luminol Solution (Bio-Rad #1705062) and Bio-Rad Molecular Imager ChemiDoc  
341 XRS detection system with Image Lab software. Quantification was performed with Image J  
342 (NIH). Antibodies and concentrations are listed in **Suppl. Table 13**.  
343

344 **Quantification of cell secretome.** Secretome samples were kept at -80°C until use. Levels of  
345 human IL-6, IL-8, MCP-1 and CX3CL1 levels assayed using the Bio-Plex Human Chemokine  
346 Assay (Bio-Rad # 171AK99MR2) according to the manufacturer's protocol. Plate was read on a  
347 Bio-Plex 3D system (Bio-Rad) with 50 bead events per well, and data reduced against a four-  
348 parameter logistic curve using the Gen 5.0 software. Samples with a coefficient of variation above  
349 20% between duplicates were removed from the analysis.  
350

351 **Illumina NovaSeq RNA-sequencing for mouse microvessels.** RNA was extracted and RNA  
352 integrity (RIN) and concentration were assessed using a Bioanalyzer. Unstranded libraries were  
353 generated, and samples sequenced with the Illumina NovaSeq 6000 system. The quality of the raw  
354 reads was assessed with FASTQC v0.12.1. After examining the quality of the raw reads, no  
355 trimming was deemed necessary. The reads were aligned to the GRCm39 reference genome with  
356 STAR v2.7.11b with mean of 76 % of reads uniquely mapped. The raw counts were calculated  
357 with FeatureCounts v2.0.6 based on the GRCm39 reference genome (release 110). Differential

358 expression was performed using DESeq2 R package. DEGs heatmap was drawn based on z-score  
359 of normalized count. Bioinformatics analyses were performed at the Bioinformatics core facility  
360 from Montreal Clinical Research Institute (IRCM). Graphs including Venn diagrams and volcano  
361 plots were generated using publicly available R packages.

362

363 **Illumina NovaSeq RNA-sequencing for human cells.** RNA was extracted with TRIzol  
364 (Invitrogen) homogenization and chloroform layer separation using the Pure Link RNA mini kit  
365 (Life Technologies), then sent to Genome Quebec. RNA integrity (RIN) and concentration were  
366 assessed using a Bioanalyzer. Quality control was performed with the Bioanalyzer, libraries  
367 generated, and samples were sequenced with the Illumina NovaSeq 6000 system. Quality of the  
368 raw reads was assessed with FASTQC v0.11.9. After examining the quality of the raw reads,  
369 trimming was performed with TRIMOMATIC v0.39. Reads were aligned to the human  
370 reference genome with STAR v2.7.9a with mean of 87 % of reads uniquely mapped. The raw  
371 counts were calculated with FeatureCounts v2.0.3 based on the human reference genome (release  
372 109). Differential expression was performed using DESeq2 R package. DEGs heatmap was drawn  
373 based on z-score of normalized count. Functional enrichment analysis of DEGs (gene ontology  
374 and pathway enrichment) was performed with the gprofiler2 R package by the Bioinformatics core  
375 facility from Montreal Clinical Research Institute (IRCM). Graphs including heatmaps, Radar  
376 charts and Circos plot were generated using publicly available R packages.

377

378 **Statistical analysis.** The sample size for CSDS, virus-injected mouse cohorts as well as cell  
379 culture studies was calculated based on previous studies<sup>1-4,17,18</sup>. For studies involving human tissue  
380 (e.g post-mortem brain tissue, sera, etc.), sample size was not calculated due to scarcity of available  
381 material. In that case, all available samples were used. All mice were assigned to stress-susceptible  
382 (SS) or resilient (RES) groups based on their behavioural profile when compared to unstressed  
383 controls (CTRL). SI screening and behavioural tests were performed with automated tracking  
384 systems when possible. If not (for splash test, sucrose preference test and forced swim test), scoring  
385 was done by experimenters blinded to experimental conditions. Outliers for behavioural testing or  
386 qPCR normalized values were identified as being greater than 2 standard deviations SD from the  
387 group mean and excluded from statistical analysis. For behavioral cohorts, an animal found to be  
388 an outlier for at least 2 behavioural tests was removed completely from all further analyses.  
389 Normality was determined by D'Agostino–Pearson, Shapiro–Wilk and Kolmogorov–Smirnov  
390 normality tests using GraphPad Prism software (version 10.0). For normally distributed datasets,  
391 t-tests, one-way ANOVAs, two-way ANOVAs, and Pearson's correlations were performed with  
392 GraphPad Prism software. Tukey was used as a post hoc test when appropriate for one-way  
393 ANOVAs. Non-normally distributed datasets were analyzed with non-parametric Mann–Whitney  
394 or Kruskal–Wallis tests for two or three groups, respectively. Dunn's was used as post hoc test  
395 when appropriate for non-parametric ANOVAs. Ficher's LSD was used as post hoc for two-way  
396 ANOVAs when appropriate. Statistical significance was set at  $p < 0.05$  with \* $p < 0.05$ ; \*\* $p < 0.01$ ;  
397 \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . P-values between 0.05 and 0.1 were considered as trending (#)  
398 without reaching significance. For detailed statistics, please refer to the Excel spreadsheet provided  
399 in the **Supplementary Information**. Heatmap representation of average and SEM in Figure 1 and  
400 others was done using Matlab-based software. Individual values were used to compute correlation  
401 matrices and p values were determined by Matlab-based software. All qPCR,  
402 immunohistochemistry and transcriptional quantification were performed in at least two different  
403 cohorts of mice. Principal component analyses (PCAs) were computed in R using the FactoMineR

404 package. Violin plots show the frequency distribution of the data. Full lines represent the median  
405 and dotted lines represent the first and third quartiles. Number of animals or subjects (n) is  
406 indicated on graphs. Source data are provided as a Source Data file.

407

408 **Data availability statement.** All data supporting the findings of the study are available within the  
409 paper and Supplementary Information files. Requests for additional information should be addressed  
410 to the corresponding author.

411

## 412 *Methods References*

---

413 1 Golden, S. A., Covington, H. E., 3rd, Berton, O. & Russo, S. J. A standardized protocol  
414 for repeated social defeat stress in mice. *Nat Protoc* **6**, 1183-1191 (2011).  
<https://doi.org/10.1038/nprot.2011.361>

415 2 Menard, C. *et al.* Social stress induces neurovascular pathology promoting depression.  
416 *Nat Neurosci* **20**, 1752-1760 (2017). <https://doi.org/10.1038/s41593-017-0010-3>

417 3 Dudek, K. A. *et al.* Molecular adaptations of the blood-brain barrier promote stress  
418 resilience vs. depression. *Proc Natl Acad Sci U S A* **117**, 3326-3336 (2020).  
<https://doi.org/10.1073/pnas.1914655117>

419 4 Dion-Albert, L. *et al.* Vascular and blood-brain barrier-related changes underlie stress  
420 responses and resilience in female mice and depression in human tissue. *Nat Commun* **13**,  
421 164 (2022). <https://doi.org/10.1038/s41467-021-27604-x>

422 5 Harris, A. Z. *et al.* A Novel Method for Chronic Social Defeat Stress in Female Mice.  
423 *Neuropsychopharmacology* **43**, 1276-1283 (2018). <https://doi.org/10.1038/npp.2017.259>

424 6 Lee, Y. K., Uchida, H., Smith, H., Ito, A. & Sanchez, T. The isolation and molecular  
425 characterization of cerebral microvessels. *Nat Protoc* **14**, 3059-3081 (2019).  
<https://doi.org/10.1038/s41596-019-0212-0>

426 7 Boergens, K. M. *et al.* webKnossos: efficient online 3D data annotation for  
427 connectomics. *Nat Methods* **14**, 691-694 (2017). <https://doi.org/10.1038/nmeth.4331>

428 8 Nikolakopoulou, A. M. *et al.* Pericyte loss leads to circulatory failure and pleiotrophin  
429 depletion causing neuron loss. *Nat Neurosci* **22**, 1089-1098 (2019).  
<https://doi.org/10.1038/s41593-019-0434-z>

430 9 Willis, E. F. & Vukovic, J. Protocol for brain-wide or region-specific microglia depletion  
431 and repopulation in adult mice. *STAR Protoc* **1**, 100211 (2020).  
<https://doi.org/10.1101/j.xpro.2020.100211>

432 10 Ravindra Kumar, S. *et al.* Multiplexed Cre-dependent selection yields systemic AAVs for  
433 targeting distinct brain cell types. *Nat Methods* **17**, 541-550 (2020).  
<https://doi.org/10.1038/s41592-020-0799-7>

434 11 Song, R. *et al.* Selection of rAAV vectors that cross the human blood-brain barrier and  
435 target the central nervous system using a transwell model. *Mol Ther Methods Clin Dev*  
436 **27**, 73-88 (2022). <https://doi.org/10.1016/j.omtm.2022.09.002>

437 12 Ji, X., Adams, S. T., Jr. & Miller, S. C. Bioluminescence imaging in mice with synthetic  
438 luciferin analogues. *Methods Enzymol* **640**, 165-183 (2020).  
<https://doi.org/10.1016/bs.mie.2020.04.033>

439 13 Bittar, T. P. *et al.* Chronic Stress Induces Sex-Specific Functional and Morphological  
440 Alterations in Corticoaccumbal and Corticotegmental Pathways. *Biol Psychiatry* **90**, 194-  
441 205 (2021). <https://doi.org/10.1016/j.biopsych.2021.02.014>

449 14 Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression  
450 severity measure. *J Gen Intern Med* **16**, 606-613 (2001). <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>

452 15 Cao, M. C. *et al.* Serum biomarkers of neuroinflammation and blood-brain barrier  
453 leakage in amyotrophic lateral sclerosis. *BMC Neurol* **22**, 216 (2022).  
<https://doi.org/10.1186/s12883-022-02730-1>

455 16 Stafford, P. *et al.* Astrocytes and pericytes attenuate severely injured patient plasma  
456 mediated expression of tight junction proteins in endothelial cells. *PLoS One* **17**,  
457 e0270817 (2022). <https://doi.org/10.1371/journal.pone.0270817>

458 17 Smyth, L. C. D. *et al.* Characterisation of PDGF-BB:PDGFRbeta signalling pathways in  
459 human brain pericytes: evidence of disruption in Alzheimer's disease. *Commun Biol* **5**,  
460 235 (2022). <https://doi.org/10.1038/s42003-022-03180-8>

461 18 Hodes, G. E. *et al.* Sex Differences in Nucleus Accumbens Transcriptome Profiles  
462 Associated with Susceptibility versus Resilience to Subchronic Variable Stress. *J  
463 Neurosci* **35**, 16362-16376 (2015). <https://doi.org/10.1523/JNEUROSCI.1392-15.2015>

464